Unmodified mRNA formulated in optimized LNPs is highly immunogenic and well tolerated in non-human primates, representing a valid platform for prophylactic vaccines.
No takes yet. Share an insight, caveat, or question.
Supports mRNA-LNP immunogenicity in NHPs; leaves open human vaccine translation.
Lutz et al. (2017) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: